(Q28270336)

Cancer immunoediting: from immunosurveillance to tumor escape

31 March 2020

1 reference

The three Es of cancer immunoediting

31 March 2020

1 reference

The immunobiology of cancer immunosurveillance and immunoediting

31 March 2020

1 reference

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

31 March 2020

1 reference

Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity

31 March 2020

1 reference

31 March 2020

The Hallmarks of Cancer

1 reference

A critical function for type I interferons in cancer immunoediting

31 March 2020

1 reference

Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development

31 March 2020

1 reference

A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas

31 March 2020

1 reference

The yin and yang of type I interferon activity in bacterial infection

31 March 2020

1 reference

Issues in T-helper 1 development--resolved and unresolved

31 March 2020

1 reference

The IFN gamma receptor: a paradigm for cytokine receptor signaling

31 March 2020

1 reference

Cellular responses to interferon-gamma

31 March 2020

1 reference

How cells respond to interferons

31 March 2020

1 reference

Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors.

31 March 2020

1 reference

Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice

31 March 2020

1 reference

Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis.

31 March 2020

1 reference

Suppression of lymphoma and epithelial malignancies effected by interferon gamma

31 March 2020

1 reference

Deficiencies of GM-CSF and Interferon γ Link Inflammation and Cancer

31 March 2020

1 reference

Gamma delta T cells provide an early source of interferon gamma in tumor immunity

31 March 2020

1 reference

Interleukin 12 and tumor necrosis factor alpha are costimulators of interferon gamma production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist

31 March 2020

1 reference

Induction of interferon-γ production in Th1 CD4+ T cells: evidence for two distinct pathways for promoter activation

31 March 2020

1 reference

Effect of interleukin 12 on tumor induction by 3-methylcholanthrene

31 March 2020

1 reference

NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma.

31 March 2020

1 reference

Increased survival in mice inoculated with tumor cells and treated with interferon preparations

31 March 2020

1 reference

Mechanism of the Antitumour Effect of Interferon in Mice

31 March 2020

1 reference

Interferon-alpha in tumor immunity and immunotherapy

31 March 2020

1 reference

Influence of anti-mouse interferon serum on the growth and metastasis of tumor cells persistently infected with virus and of human prostatic tumors in athymic nude mice

31 March 2020

1 reference

Injection of mice with antibody to interferon enhances the growth of transplantable murine tumors

31 March 2020

1 reference

Enhanced tumor development in mice lacking a functional type I interferon receptor

31 March 2020

1 reference

Rules for making human tumor cells

31 March 2020

1 reference

Cancer genes and the pathways they control

31 March 2020

1 reference

NKG2D function protects the host from tumor initiation

31 March 2020

1 reference

Differential tumor surveillance by natural killer (NK) and NKT cells.

31 March 2020

1 reference

Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance.

31 March 2020

1 reference

IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression

31 March 2020

1 reference

Molecular characterization of defective antigen processing in human prostate cancer.

31 March 2020

1 reference

Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma.

31 March 2020

1 reference

Decreased STAT1 expression by promoter methylation in squamous cell carcinogenesis

31 March 2020

1 reference

STAT5 contributes to interferon resistance of melanoma cells.

31 March 2020

1 reference

Antigen-processing machinery breakdown and tumor growth

31 March 2020

1 reference

The HLA crossroad in tumor immunology

31 March 2020

1 reference

Expression of SOCS-1, suppressor of cytokine signalling-1, in human melanoma

31 March 2020

1 reference

Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis

31 March 2020

1 reference

IFN-gamma-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-gamma

31 March 2020

1 reference

IFN-dependent down-regulation of the NKG2D ligand H60 on tumors

31 March 2020

1 reference

Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1.

31 March 2020

1 reference

Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma

31 March 2020

1 reference

Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis

31 March 2020

1 reference

p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-gamma

31 March 2020

1 reference

IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo

31 March 2020

1 reference

CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma

31 March 2020

1 reference

Cutting edge: spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice

31 March 2020

1 reference

IFN-gamma controls the generation/activation of CD4+ CD25+ regulatory T cells in antitumor immune response.

31 March 2020

1 reference

CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses

31 March 2020

1 reference

Paradoxical roles of the immune system during cancer development

31 March 2020

1 reference

Oxidative and nitrative DNA damage in animals and patients with inflammatory diseases in relation to inflammation-related carcinogenesis

31 March 2020

1 reference

IL-23 promotes tumour incidence and growth

31 March 2020

1 reference

IFNgamma-dependent, spontaneous development of colorectal carcinomas in SOCS1-deficient mice

31 March 2020

1 reference

Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. I.

31 March 2020

1 reference

The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse

31 March 2020

1 reference

The role of type I interferons in non-viral infections

31 March 2020

1 reference

Clinical translation of angiogenesis inhibitors

31 March 2020

1 reference

Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence.

31 March 2020

1 reference

Implications for RNase L in prostate cancer biology

31 March 2020

1 reference

Germline mutations in the ribonuclease L gene in families showing linkage with HPC1

31 March 2020

1 reference

RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases

31 March 2020

1 reference

RETRACTED: Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant

31 March 2020

1 reference

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

31 March 2020

1 reference

Prognostic significance of autoimmunity during treatment of melanoma with interferon.

31 March 2020

1 reference

Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group

31 March 2020

1 reference

Controlled clinical trial of interferon-gamma as postoperative surgical adjuvant therapy for colon cancer

31 March 2020

1 reference

Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer

31 March 2020

1 reference

Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial

31 March 2020

1 reference

Isolated limb perfusion in primary and recurrent melanoma: indications and results

31 March 2020

1 reference

The DNA damage response arouses the immune system

31 March 2020

1 reference

Two contact regions between Stat1 and CBP/p300 in interferon gamma signaling

31 March 2020

1 reference

Identification of two residues in MCM5 critical for the assembly of MCM complexes and Stat1-mediated transcription activation in response to IFN-gamma

31 March 2020

1 reference

SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine.

31 March 2020

1 reference

SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality

31 March 2020

1 reference

PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity.

31 March 2020

1 reference

Mechanisms of type-I- and type-II-interferon-mediated signalling

31 March 2020

1 reference

Interferons, interferon-like cytokines, and their receptors

31 March 2020

1 reference

Partial impairment of cytokine responses in Tyk2-deficient mice

31 March 2020

1 reference

Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function

31 March 2020

1 reference

Regulation of cutaneous malignancy by gammadelta T cells

31 March 2020

1 reference

The distinct contributions of murine T cell receptor (TCR)gammadelta+ and TCRalphabeta+ T cells to different stages of chemically induced skin cancer

31 March 2020

1 reference

Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma

31 March 2020

1 reference

Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts

31 March 2020

1 reference

Enhanced tumorigenesis in HTLV-1 tax-transgenic mice deficient in interferon-gamma

31 March 2020

1 reference

Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells

31 March 2020

1 reference

Decreased tumor surveillance in perforin-deficient mice

31 March 2020

1 reference

Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice

31 March 2020

1 reference

Cutting Edge: TRAIL Deficiency Accelerates Hematological Malignancies

31 March 2020

1 reference

Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis

31 March 2020

1 reference

Plasmacytoid dendritic cells: in search of their niche in immune responses

31 March 2020

1 reference

The roles of IFN gamma in protection against tumor development and cancer immunoediting

31 March 2020

1 reference